Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy
Latest Information Update: 06 Sep 2021
At a glance
- Drugs Gefitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms COG; HANDEL; TRANS-COG
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 24 May 2017 Primary endpoint (Overall Survival in EGFR FISH (fluorescent in situ hybridization)-negative patients for TRANSCOG sub-study) has not been met, according to results published in the Journal of Clinical Oncology.
- 24 May 2017 Primary endpoint (Overall Survival in EGFR FISH (fluorescent in situ hybridization)-positive patients for TRANSCOG sub-study) has been met, according to results published in the Journal of Clinical Oncology.